8-K: Axsome Therapeutics Initiates Phase 3 Trial of Solriamfetol for Binge Eating Disorder

Axsome Therapeutics has commenced a Phase 3 clinical trial, named ENGAGE, to evaluate solriamfetol as a potential treatment for binge eating disorder in adults.

Summary

• Axsome Therapeutics has begun the ENGAGE Phase 3 trial to study solriamfetol for binge eating disorder.
• The trial is a randomized, double-blind, placebo-controlled, multicenter study.
• Approximately 450 adult patients will be enrolled and randomly assigned to receive either 150mg or 300mg of solriamfetol, or a placebo, for 12 weeks.
• The primary goal of the trial is to measure the change in the number of binge eating episodes.
• The first patient was screened for the ENGAGE trial in March 2024.
• Binge eating disorder affects an estimated 2.8% of U.S. adults, or about 7 million people, and is more common in women.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the initiation of a Phase 3 trial, but tempered by the inherent risks and uncertainties of drug development.

Positives

• The initiation of the Phase 3 trial represents a significant step in the development of a potential new treatment for binge eating disorder.
• Solriamfetol has a novel mechanism of action as a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist.
• The trial is well-designed as a randomized, double-blind, placebo-controlled, multicenter study.

Negatives

• Solriamfetol is not yet approved by the FDA for the treatment of binge eating disorder.
• The trial results are not guaranteed and may not demonstrate the efficacy of solriamfetol.

Risks

• The success of the trial is subject to risks and uncertainties, including the pace of enrollment and the final results.
• There is a risk that the trial may not demonstrate the efficacy of solriamfetol.
• The company's ability to fund additional clinical trials is dependent on its financial performance.
• Regulatory approval of solriamfetol is not guaranteed.

Future Outlook

The company is focused on the continued development of solriamfetol and other product candidates, but the success of these efforts is subject to various risks and uncertainties.

Management Comments

• Axsome is committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians.

Industry Context

This announcement is relevant to the pharmaceutical industry's focus on developing treatments for central nervous system disorders, particularly eating disorders, which have limited treatment options. The trial is part of a broader effort to address the unmet needs of patients with binge eating disorder.

Comparison to Industry Standards

• The ENGAGE trial is a standard Phase 3 clinical trial design, similar to those used by other pharmaceutical companies developing treatments for CNS disorders.
• The use of a randomized, double-blind, placebo-controlled design is consistent with industry best practices for clinical trials.
• The trial's focus on a specific endpoint, the change in binge eating episodes, is a common approach in clinical trials for eating disorders.
• Other companies such as Shire (now Takeda) with Vyvanse have previously targeted this market, and the results of this trial will be compared to those of existing treatments.

Stakeholder Impact

• The trial has the potential to benefit patients with binge eating disorder by providing a new treatment option.
• Positive trial results could increase shareholder value.
• The trial may create new opportunities for physicians to treat patients with binge eating disorder.

Next Steps

• The company will continue to enroll patients in the ENGAGE trial.
• The company will monitor the progress of the trial and report results as they become available.

Key Dates

Keywords

Solriamfetol, Binge Eating Disorder, Phase 3 Trial, ENGAGE, Axsome Therapeutics, CNS Disorders, Clinical Trial, FDA, Treatment